0.05). The number of cases of moderately differentiated adenocarcinoma in the young group was less than in the other group (p0.1). The study shows that after radical resection the 5 years survival rate is the same in the two groups. Thus, for improvement of survival rate of young persons with rectal carcinoma, it is important to make an early diagnosis and perform radical resection of the lesion.

Objective To investigate the principle and method of breast-concerving therapy of early-stage breast cancer.Methods The clinical data of 31 cases of early-stage breast cancer who were conserved breast were analysed retrospectively from January 1992 to April 2002. 14 cases performed wide lumpectomy plus axillary nodes dissection,5 cases performed wide lumpectomy, 11 cases performed lumpectomy and 1 case did not perform operation. After operation 17 cases received radiotherapy and chemotherapy,8 cases received only radiotherapy,3 cases received only chemotherapy and 3 cases did not receive radio-chemotherapy.Results Surviving time of all patients was 6 to 122 months.Mean surviving time was 32?5 months.Median of survival time was 22 months.Among 31 patients 1 case died of metastasis due to refusing chemotherapy,the other were alive now and 10 cases of all patients have survival over 3 years. Local recurrence was found in 1 case after 5 years,but he did not take chemotherapy and radiotherapy. Fairly good cosmetic outcome was obtained in 29 patients(93 5%).Conclusions It probably is ideal method that the wide lumpectomy plus axillary nodes dissection combines rationally with radiotherapy and chemotherapy in breast-conserving treatment of early- stage breast cancer.

0 05).buprenorphine buccal produced less nausea and vomiting than those in the other route(P0 05).The changes of the vital signs in two groups were not clinically important. Conclusions The study indicates that the analgesia effects of buprenorphine sublingual administered is same as intramuscular buprenorphine,but the buprenorphine buccal is more convenient.However,the drug dependence terdency should be monitored.

0 05) The histological types in these two groups were not significantly different, except that there were more well differentiated adenocarcinoma in SSO group than that in APR group ( P 0 05). However,the 5 years survival rate (79% in SSO,67% in APR) was significantly different (P

Objective To evaluate the prognostic factors affecting recurrence,progression,bladder preservation,metastasis and cancer specific survival in patients with primary superficial transitional cell carcinoma of bladder. Methods Using Kaplan Meier method,Log rank test and Cox proportional hazards model,the retrospective survival analysis was performed in 198 patients with primary superficial transitional cell carcinoma of bladder. Results The mean follow up period was 79.76 months.The recurrence rates at 3 ,5 ,10 year were (28.75?0.78)%,(35.70?0.16)%,and (42.83?0.00)%,respectively.The main variables affecting recurrence were the duration of symptoms,histological grades and intra operative blood transfusion.The progression rates at 3 ,5 ,10 year were(8.89?0.33)%,(15.16?0.16)%,and (23.88?0.00)%,respectively.The main variables affecting progression were intra operative blood transfusion,histological grades,the number of reexaminations and recurrence free period (RFP).The rates of bladder preservation at 3 ,5 ,10 year were(94.68?0.23)%,(93.87?0.00)%,(91.51?0.00)%,respectively. The main variable affecting bladder preservation was RFP. The metastasis rates at 3 ,5 ,10 year were (8.25?0.22)%,(11.24?0.00)%,(28.94?0.00)%,respectively.The main variables affecting metastasis were tumor multifocality, hydronephrosis,microscopic growth pattern and RFP. The cancer specific survival at 3 ,5 ,10 year were (95.02?0.00)%,(90.70?0.46)%,(77.14?1.06)%,respectively.The variables that could predict cancer specific survival were microscopic growth pattern and RFP. Conclusions By cancer specific survival analysis of the follow up data,we can well identify the main prognostic factors from numerous ones,and also can design the therapeutic and follow up strategies for primary superficial transitional cell carcinoma of bladder.